Literature DB >> 11091213

Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia.

S Mizuno1, N Emi, M Kasai, A Ishitani, H Saito.   

Abstract

We have analysed the expression of HLA-G in 40 leukaemia samples of various subtypes [seven cases of acute lymphoblastic leukaemia (ALL), 28 cases of acute myelogenous leukaemia (AML), three cases of chronic myelogenous leukaemia (CML) and two cases of chronic lymphocytic leukaemia (CLL)] by flow cytometry using HLA-G-specific monoclonal antibody. No leukaemia samples expressed HLA-G without incubation with interferon (IFN)-gamma. However, six out of 28 (21%) AML samples expressed HLA-G upon incubation with IFN-gamma. These six samples derived from one out of seven M2, two out of eight M4 and three out of five M5. The results indicated that AML cells, especially myelomonocytic leukaemia samples, are capable of expressing the HLA-G molecule.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11091213     DOI： 10.1046/j.1365-2141.2000.02345.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

2.  Role and expression of non-classical human leukocyte antigen-G in renal transplanted allografts.

Authors:  Sho Kumano; Yuki Okushi; Keiji Fujimoto; Hiroki Adachi; Kengo Furuichi; Hitoshi Yokoyama
Journal:  Clin Exp Nephrol       Date:  2021-01-04       Impact factor: 2.801

3.  Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.

Authors:  Catherine Matte-Martone; Jinling Liu; Meng Zhou; Maria Chikina; Douglas R Green; John T Harty; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

Review 4.  Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

Authors:  Laurence Amiot; Soldano Ferrone; Hans Grosse-Wilde; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2010-11-10       Impact factor: 9.261

5.  Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages.

Authors:  Frédéric Gros; Yasmine Sebti; Sophie de Guibert; Bernard Branger; Marc Bernard; Renée Fauchet; Laurence Amiot
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

6.  HLA-G expression in acute lymphoblastic leukemia: a significant prognostic tumor biomarker.

Authors:  Noura Alkhouly; Iman Shehata; Manal Basyouni Ahmed; Hanan Shehata; Sara Hassan; Tamer Ibrahim
Journal:  Med Oncol       Date:  2013-01-19       Impact factor: 3.064

7.  HLA-G does not have a pathophysiological role in Graves' disease.

Authors:  E H Kemp; R A Metcalfe; P F Watson; A P Weetman
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

8.  Determination of HLA-G Expression and Evaluation of Its Role as a Prognostic Factor in Chronic Lymphocytic Leukemia.

Authors:  Gulsum Ozet; Mesude Falay; Simten Dagdas; Funda Ceran
Journal:  J Clin Lab Anal       Date:  2015-08-24       Impact factor: 2.352

9.  Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia.

Authors:  W-H Yan; A Lin; B-G Chen; W-D Luo; M-Z Dai; X-J Chen; H-H Xu; B-L Li
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

10.  HLA-G expression on blasts and tolerogenic cells in patients affected by acute myeloid leukemia.

Authors:  Grazia Locafaro; Giada Amodio; Daniela Tomasoni; Cristina Tresoldi; Fabio Ciceri; Silvia Gregori
Journal:  J Immunol Res       Date:  2014-03-13       Impact factor: 4.818
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.